Supported by an educational grant from Abbott Laboratories.
Article first published online: 28 NOV 2010
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 6, pages 1415–1422, June 2011
How to Cite
Pariente, B., Cosnes, J., Danese, S., Sandborn, W. J., Lewin, M., Fletcher, J. G., Chowers, Y., D'Haens, G., Feagan, B. G., Hibi, T., Hommes, D. W., Irvine, E.Jan., Kamm, M. A., Loftus, E. V., Louis, E., Michetti, P., Munkholm, P., Oresland, T., Panés, J., Peyrin-Biroulet, L., Reinisch, W., Sands, B. E., Schoelmerich, J., Schreiber, S., Tilg, H., Travis, S., van Assche, G., Vecchi, M., Mary, J.-Y., Colombel, J.-F. and Lémann, M. (2011), Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis, 17: 1415–1422. doi: 10.1002/ibd.21506
Conflicts of interest: William Sandborn, Yehuda Chowers, Edward V. Loftus, Jr., Edouard Louis, Tom Oresland, Julián Panés, Walter Reinisch, Simon Travis, Maurizio Vecchi, Jean Frederic Colombel, and Marc Lemann, have received research support from and served as consultants to Abbott Laboratories.
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- Issue published online: 10 MAY 2011
- Article first published online: 28 NOV 2010
- Manuscript Accepted: 30 AUG 2010
- Manuscript Received: 6 AUG 2010
- Abbott Laboratories
- Crohn's disease;
- illness index severity;
- magnetic resonance imaging
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article is to outline the methods to develop an instrument that can measure cumulative bowel damage. The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) group. This instrument, called the Crohn's Disease Digestive Damage Score (the Lémann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection. It should not be “diagnostic modality driven”: for each lesion and location, a modality appropriate for the anatomic site (for example: computed tomography or magnetic resonance imaging enterography, and colonoscopy) will be used. A total of 24 centers from 15 countries will be involved in a cross-sectional study, which will include up to 240 patients with stratification according to disease location and duration. At least 120 additional patients will be included in the study to validate the score. The Lémann score is expected to be able to portray a patient's disease course on a double-axis graph, with time as the x-axis, bowel damage severity as the y-axis, and the slope of the line connecting data points as a measure of disease progression. This instrument could be used to assess the effect of various medical therapies on the progression of bowel damage. (Inflamm Bowel Dis 2011)